Clinical Trial Results:
INCENTIVE-QIV-3-EU: Immunogenicity, molecular profiling of a marketed quadrivalent influenza vaccine (Vaxigrip Tetra®) administered by the intramuscular route in participants aged 6 to 8 months
Summary
|
|
EudraCT number |
2021-003760-27 |
Trial protocol |
BE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
06 Feb 2025
|
First version publication date |
09 Jan 2025
|
Other versions |
v1 |
Version creation reason |
|
Summary report(s) |
INCENTIVE_QIV-3_CSR_20DEC2024_version 1.0 Annex I_Incentive QIV3_ICF_EN_v4.0 Annex II_Investigator signatures Annex III_SmPC Vaxigrip Tetra 2021 Annex III_SmPC Vaxigrip Tetra 2022 Annex IV_Vaccine and HAI strains |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.